Table 1.

Respondent characteristics.

CharacteristicsAllInflammatory rheumatic disease patients
(n=591)(%)(n=453)(%)
Female gender, n (%)353(59.7)286(63.1)
Age, median (IQR), years59.0(51.0-67.0)60.0(51.0-67.5)
BiologicsAdalimumab220(37.2)164(36.2)
Etanercept196(33.2)189(41.7)
Infliximab43(7.3)8(1.8)
Tocilizumab21(3.6)17(3.8)
Ustekinumab21(3.6)7(1.5)
Other90(15.2)68(15.0)
Combination therapyMethotrexate195(33.0)183(40.4)
Corticosteroids65(11.0)51(11.3)
Thiopurines41(6.9)10(2.2)
No combination therapy231(39.1)157(34.7)
Other123(20.8)106(23.4)
Indications for biologic therapyRheumatoid arthritis277(46.9)277(61.1)
Psoriatic arthritis111(18.8)111(24.5)
Ankylosing spondylitis/axSpA83(14.0)83(18.3)
Other159(26.9)17(3.8)
  • IQR: interquartile range; axSpA: axial spondyloarthritis.